Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE).
Staehler M, Basso U, Eymard JC, Barthelemy P, Bigot P, Laramas M, Rink M, Suarez C, Guillot A, Bedke J, Hamberg P, De Vivo R, Gajate P, Lázaro-Quintela M, Rastogi P, Perrot V, Qvick B, Dutailly P, Verzoni E, Procopio G. Staehler M, et al. Among authors: eymard jc. Clin Genitourin Cancer. 2024 Nov 30;23(1):102285. doi: 10.1016/j.clgc.2024.102285. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39740313 Free article.
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Choueiri TK, et al. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851. N Engl J Med. 2023. PMID: 37163623 Free PMC article. Clinical Trial.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D; CARD Investigators. de Wit R, et al. Among authors: eymard jc. N Engl J Med. 2019 Dec 26;381(26):2506-2518. doi: 10.1056/NEJMoa1911206. Epub 2019 Sep 30. N Engl J Med. 2019. PMID: 31566937 Clinical Trial.
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment.
Barthélémy P, Thibault C, Fléchon A, Gross-Goupil M, Voog E, Eymard JC, Abraham C, Chasseray M, Lorgis V, Hilgers W, Gobert A, Le Moulec S, Simon C, Nicolas E, Escande A, Pouessel D, Mouillet G, Josse C, Solbes MN, Lambert P, Loriot Y. Barthélémy P, et al. Among authors: eymard jc. Eur Urol Oncol. 2024 Oct 23:S2588-9311(24)00223-2. doi: 10.1016/j.euo.2024.09.014. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39448350 Free article.
[Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations].
Oudard S, Timsit MO, Maillet D, Mouillet G, Campedel L, Colomba É, Dourthe LM, Eymard JC, Gobert A, Jamet C, Joly C, Serrate C, Ploussard G. Oudard S, et al. Among authors: eymard jc. Bull Cancer. 2025 Jan;112(1):61-81. doi: 10.1016/j.bulcan.2024.05.008. Epub 2024 Sep 3. Bull Cancer. 2025. PMID: 39232886 Free article. Review. French.
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.
Fizazi K, Le Teuff G, Fléchon A, Pagliaro L, Mardiak J, Geoffrois L, Laguerre B, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Cancel M, Juzyna B, Reckova M, Naoun N, Logothetis C, Culine S. Fizazi K, et al. Among authors: eymard jc. J Clin Oncol. 2024 Oct;42(28):3270-3276. doi: 10.1200/JCO.23.01960. Epub 2024 Aug 21. J Clin Oncol. 2024. PMID: 39167741 Clinical Trial.
Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study.
Barthélémy P, Albigès L, Escudier B, Narciso B, Bigot P, Chehimi M, Emambux S, Calcagno F, Mouillet G, Eymard JC, Schlürmann F, Bailly S, Garbay D, Berdah JF, Palmaro MB, Goupil MG, Spaeth D, Néré S, Quentric C, Vano YA, Thiery-Vuillemin A. Barthélémy P, et al. Among authors: eymard jc. ESMO Open. 2024 Jul;9(7):103602. doi: 10.1016/j.esmoop.2024.103602. Epub 2024 Jun 18. ESMO Open. 2024. PMID: 38897136 Free PMC article.
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21. Lancet Oncol. 2024. PMID: 38142702 Clinical Trial.
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
Colomba E, Jonas SF, Eymard JC, Delva R, Brachet PE, Neuzillet Y, Penel N, Roubaud G, Bompas E, Mahammedi H, Longo R, Helissey C, Barthélemy P, Borchiellini D, Hasbini A, Priou F, Saldana C, Voog E, Narcisso B, Ladoire S, Berdah JF, Aisenfarb JB, Foulon S, Fizazi K. Colomba E, et al. Among authors: eymard jc. Eur Urol. 2024 Mar;85(3):274-282. doi: 10.1016/j.eururo.2023.05.009. Epub 2023 Jun 2. Eur Urol. 2024. PMID: 37271630 Clinical Trial.
111 results